NCT02490748Active, not recruitingPhase 2
Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Enrollment
- 10
- Primary Endpoint
- Recurrence-free survival
Study Overview
Brief Summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.
Detailed Description
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cervical cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 30 Years to 70 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer.
- •they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer).
Exclusion Criteria
- •studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.
Outcomes
Primary Outcomes
Recurrence-free survival
Time Frame: 1 year
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 2
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver MetastasesColorectal CancerNCT02419677The First People's Hospital of Changzhou60
Active, not recruiting
Phase 2
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With CholangiocarcinomaCholangiocarcinomaNCT02482454The First People's Hospital of Changzhou50
Active, not recruiting
Phase 2
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian CarcinomaOvarian CarcinomaNCT02487693The First People's Hospital of Changzhou50
Unknown
Phase 4
Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular CarcinomaLiver CancerHepatocellular CarcinomaNCT00554905Sun Yat-sen University180
Withdrawn
Phase 4
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver MetastasesMetastatic Liver CancerSecondary Liver CancerLiver NeoplasmNCT00510627Boston Scientific Corporation